Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis

AbstractFluoro-deoxy glucose positron emission tomography/computed tomography (PET/CT), the workhorse of nuclear medicine, has limited utility for renal cell carcinoma (RCC), particularly clear cell variant. Thus, various other tracers have been  tried for evaluation of RCC. One of the most promising targets for radiotracers is prostate-specific membrane antigen (PSMA) expressed in abundance in carcinoma-associated neo-vasculature. Thus, we tried to review and analyse the role of PSMA-targeted PET/CT in evaluation of RCC. Databases like Pu bMed, EMBASE and SCOPUS were searched for original studies published on PSMA-targeted PET/CT in RCC till 30 September 2023. Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) checklist was used to assess the included studies. Pooled sensitivity and specificity were c alculated and represented with 95% confidence intervals (95%CI). Heterogeneity in the studies was assessed byI-square index. Pooled sensitivity and specificity of PSMA-targeted PET/CT for detection of local disease estimates were 87.2% (95%CI: 77 –94%) and 100% (95%CI: 92.9–100%), respectively. Pooled sensitivity and specificity for detection of local recurrent disease are 100% (95%CI: 71.5–100%) and 100% (95%CI: 89.4–100%), respectively. Pooled sensitivity and specificity for detection of metastatic disease are 92% (95%CI: 86.2–96 %) and 96.9% (95%CI: 83.8–99.9%), respectively. Pooled sensitivity of PSMA-targeted PET/CT for detecti...
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research